X

Trial Profile

A phase II/III randomised, double blinded, placebo controlled trial of gemcitabine/ [+] carboplatin with or without thalidomide in advanced non-small cell lung cancer.

Status: Completed

Phase of Trial: Phase II/III

Latest Information Update: 02 Nov 2021

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Gemcitabine (Primary) ; Thalidomide (Primary) ; Carboplatin
Indications Non-small cell lung cancer
Focus Biomarker; Therapeutic Use

Most Recent Events

21 Sep 2009 Primary endpoint 'Overall survival' has not been met according to results published in the Journal of Clinical Oncology.
21 Sep 2009 Results published online by the Journal of Clinical Oncology.
21 Sep 2009 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com